1. The Effect of Luteinising Hormone Suppression in In Vitro Fertilisation Antagonist Cycles
- Author
-
Jessie Wai Leng Phoon, Jill Cheng Sim Lee, John Carson Allen, Sadhana Nadarajah, Jerry Kok Yen Chan, Jody Paige Goh, Shuling Liu, and Xiang Wen Ng
- Subjects
0301 basic medicine ,medicine.medical_specialty ,media_common.quotation_subject ,medicine.medical_treatment ,Ovarian hyperstimulation syndrome ,Controlled ovarian hyperstimulation ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Ganirelix ,Ovulation ,Menstrual cycle ,media_common ,030219 obstetrics & reproductive medicine ,In vitro fertilisation ,business.industry ,Antagonist ,Obstetrics and Gynecology ,medicine.disease ,030104 developmental biology ,Endocrinology ,Ovulation induction ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
Use of GnRH antagonists in IVF stimulation protocols shortens controlled ovarian hyperstimulation (COH) and reduces the risk of ovarian hyperstimulation syndrome (OHSS). However, profound reduction in LH levels has been associated with use of GnRH antagonists. This study aims to determine if LH suppression during GnRH antagonist cycles results in poorer IVF outcomes. This was a prospective pilot longitudinal study where serum LH levels were measured on day 2/3 of the menstrual cycle before COH, 1/2 days following institution of GnRH antagonist and at the day of ovulation trigger. A threshold of LH
- Published
- 2021
- Full Text
- View/download PDF